Am­gen kicks back I/O drug at cen­ter of $500M deal, leav­ing biotech part­ner alone to pon­der next steps

Just ahead of a planned Phase I read­out, Am­gen is punt­ing back an im­muno-on­col­o­gy drug to Mol­e­c­u­lar Part­ners.

Am­gen cit­ed a “strate­gic pipeline re­view” for the de­ci­sion to re­turn rights to MP0310, pre­vi­ous­ly named AMG 506, to the biotech. Like the rest of Mol­e­c­u­lar Part­ners’ pipeline, it’s a DARPin — an en­gi­neered an­ti­body mimet­ic pro­tein — but it specif­i­cal­ly binds to fi­brob­last ac­ti­va­tion pro­tein (FAP) on tu­mor stro­mal cells and 4-1BB on T cells.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER